The Pathfinder retweeted
$IDYA IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint
•Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint
•IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC
•Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively
•IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026
The Pathfinder retweeted
It’s a privilege to be able to share our Atlas Venture 2026 Year In Review.
- Capital markets: Biotech is Back… we hope
- innovation industry: patient impact
- Atlas Venture: doing well by doing good
lifescivc.com/2026/11/atlas-…
The Pathfinder retweeted
$PEPG $125M offering priced at $5/share
$DCTH obviously a Q3 blowout. I think Q4 guidance is way too conservative given new starts. Love move into ICC (8x to 10x larger than mUm) w/ good historical evidence from IHP & CHEMOSTAT; cRc interim moved to mid 27 (from late 27); Believe CHOPIN add to NCCN still in cards
The Pathfinder retweeted
$VIR
$VIR came to kick some ass, apparently…
a back to de Backer PR:
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
$VIR
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
Editor: strong case to be made that $VIR is best in class/disease vis a vis $GILD, $MIRM
- Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment
- 100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus (as defined by HDV RNA TND) at Week 48
$xbi
The Pathfinder retweeted
Today, Xeris Biopharma announced financial results and business highlights for the third quarter ended September 30, 2026. To learn more, read the press release at bit.ly/4sH3SrN. $XERS
The Pathfinder retweeted
$AXSM Q3 results. globenewswire.com/news-relea…
The Pathfinder retweeted
"They’re orchestrating a wealth transfer. The stock didn’t even trade—they just gapped it down 20% while the market was closed." $INTC
The Pathfinder retweeted
"I don’t think the reaction is appropriate to the earnings outcome. Most likley are the Democrats trying to crash the market to get more votes." $INTC
The Pathfinder retweeted
Today we announced positive Phase 1 study results for two novel, non-opioid pain candidates targeting Nav1.7 and Kv7 and plans to advance both candidates to Phase 2 proof-of-concept studies.
Read the press release: investor.xenon-pharma.com/ne…
@IASPpain #WC2026
The Pathfinder retweeted
$ROIV first expansion test for Lisraya passes.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
investor.roivant.com/news-re…
The Pathfinder retweeted
"What we learn from history is that people don't learn from history."
— Warren Buffett
The Pathfinder retweeted
President Trump’s decision to lift sanctions on Russian fuel amidst Putin’s ongoing and brutal attacks on civilian targets in Ukraine makes no sense and is a betrayal of the legacy and leadership of the late Senator Lindsey Graham.
While Ukraine fights for its survival, Putin’s war machine continues to prosecute his terrorist war on civilian populations and innocent Ukrainians are dying every day.
Now, Instead of implementing the tough sanctions Lindsey Graham fought to his last breath to enact, President Trump has announced the United States is lifting sanctions on Russian energy, fueling the Putin’s war machine.
As I saw firsthand in Ukraine last month, Putin is losing this war. Ukraine has fought the Russian military to a standstill and reinvented warfare with drones taking the fight into the heart of Russia.
America should not be throwing a lifeline to Putin’s war machine. Now is the time to stand strong against Russian aggression as we did during the first Trump administration.
Putin doesn’t want peace. Putin wants Ukraine. I have no doubt that if Putin overruns Ukraine, it will only be a matter of time until Russia’s military crosses a border that our troops will have to deal with him.
America is the Leader of the Free World. For our National Security, for the security of our Allies in Europe including Ukraine, President Trump should rescind this deal immediately and return to the strong policies of our four years in the White House; impose harsh sanctions on any nation purchasing Russian energy and work with our allies to ensure Ukraine has the military support it needs to repel and defeat this Russian invasion once and for all. Slava Ukraini🇺🇸🇺🇦
The Pathfinder retweeted
3/ $OVID
Two shots on goal. A year-end PPR epilepsy readout for OV329, where ~50 years of data say a clean PPR read reliably translates to real anti-seizure efficacy. And the one we're most intrigued by: the OV4071 KCC2 ketamine challenge in early '27.
The CEO's framing on KCC2: it could be "a $KRTX or a Cobenfy times five." If she's even half right, that's a very big idea the market is pricing at almost nothing.
The Pathfinder retweeted
$XERS H Lundbeck (HLBBF) has expressed interest in purchasing the commercial-stage drugmaker. The Danish pharma firm has been working with advisers to explore an acquisition of Chicago-based Xeris (XERS), according to a Bloomberg report on Tuesday, which cited people familiar with the matter. A spokeswoman for Xeris (XERS) told Bloomberg the company is “not for sale” and is “laser focused on improving patient lives by developing and commercializing” its medicines. Xerix (XERS) has a market cap of $1.79 billion, while Lundbeck has a value of 43.3 billion Danish kroner ($6.6 billion).






































